Rhythm Technologies (Nasdaq:IRTC) announced that the FDA granted 510(k) clearance for Zio AT design modifications and ...

The Zio AT wireless patch device is cleared by the FDA for continuous monitoring of heart rhythms in non-critical care patients during daily activities, where real-time monitoring is not needed. Data ...

SAN FRANCISCO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and ...

根据最近向美国证券交易委员会(SEC)提交的8-K文件,医疗设备和服务提供商iRhythm Technologies, Inc.对其公司治理结构进行了重大修改。这家以外科和医疗器械板块工作而闻名的公司修订了其2016年股权激励计划,并更新了行为准则。 2024年11月7日,在薪酬和人力资本管理委员会的建议下,iRhythm董事会批准了对2016年股权激励计划的修订,取消了可发行股份数量的自动年度增 ...

Quentin Blackford, President and CEO of iRhythm, stated, "This clearance is related to modifications and certain enhancements to our Zio AT device previously made via letter to file and has been a ...

The Zio AT services are provided by iRhythm’s independent diagnostic testing facilities located in San Francisco, California, Deerfield, Illinois and Houston, Texas.

iRhythm's stock surged over 20% today after the FDA cleared its 510(k) submission for the Zio AT device, despite ongoing regulatory challenges. The company still faces significant hurdles ...

“This clearance is related to modifications and certain enhancements to our Zio AT device previously made via letter to file and has been a priority for our teams to demonstrate iRhythm’s ...

iRhythm Technologies, Inc. IRTC has received FDA 510(k) clearance for design changes and enhancements previously made to its ...

The Zio AT services are provided by iRhythm's independent diagnostic testing facilities located in San Francisco, California, Deerfield, Illinois and Houston, Texas. Zio Services' Clinically ...